AMD shares jump 8% on $100B+ AI chip deal with Meta SiliconANGLE

Grandbrothers/iStock Editorial via Getty Images Hims & Hers Health, Inc. ( HIMS ) has seen the stock make a huge reversal after an initial post-Q4 selloff. The online health and wellness platform is full-speed ahead on growth initiatives while the stock market is stuck in the weeds focusing on short-term regulatory hiccups. My i nvestment thesis remains ultra Bullish on the stock after Hims & Hers Health has lost nearly 80% from the 52-week highs. Source: Finviz Sailing Along Hims went into the quarterly report with the market obsessing over some self-inflicted wounds over GLP-1s. The company left the earnings call with a solid path thru 2030 and clear sight of the financial targets: revenue of $6.5 billion and adjusted EBITDA of $1.3 billion. The company reported the following Q4 2025 results : Source: Seeking Alpha As expected, Hims reported Q4 numbers generally in line with expectations. The company ran into the oral GLP-1 issue in early February , so any hits from the potential DOJ and FDA regulatory actions wouldn't start until Q1 and likely much farther into the future. Naturally, the market was going to look at guidance to see how much of the business was hampered by the regulatory warnings. Not surprisingly, the answer was nothing, as the oral GLP-1 product never got fully launched before Hims pulled the product. Hims guided to a mixed picture for Q1 2026, likely contributing to the initial stock selloff following earnings, but the quarterly weakness is explained by a change in GLP-1 shipping timelines. On the Q4 2025 earnings call , CEO Andrew Dudum outlined the headwind as follows (emphasis added): Behind our outlook are the following assumptions: first, we expect an approximately $65 million revenue headwind in the first quarter, resulting from the change in shipping cadences in our weight loss business following the shift to 503(a) fulfillment. For context, in the second half of 2025, this revenue headwind was approximately $40 million. We expect this ef...

Shares of computer processor maker Intel (NASDAQ:INTC) jumped 5.4% in the afternoon session after the semiconductor sector received a major boost as Advanced Micro Devices (AMD) secured a deal to sell up to US$60 billion in artificial intelligence chips to Meta Platforms over five years.

Why Is Intel (INTC) Stock Soaring Today Yahoo Finance

【有線新聞】電動車「一換一」計劃再有調整，財政司司長陳茂波宣布，電動私家車首次登記稅寬減到三月底結束，不會再延續。至於電動商用車及電單車全數豁免就到2028年3月底。 電動車「一換一」計劃兩年前延續時寬減已經下調，計劃將於下月底屆滿。預算案公布，電動私家車首次登記稅寬減在下月底屆滿後不會再繼續，電動商用車、電動電單車及三輪車就會繼續全數豁免至2028年3月底。陳茂波：「考慮到現時電動私家車技術成熟、供應充足、車款增加及價格逐漸下調，電動私家車已具備市場競爭力。」 截至去年底，全港有約14.9萬輛電動車，佔所有車輛總數超過16%。消息人士相信短期難免影響市民買電車意欲，錯覺多付稅款，但計劃自1994年起推出，現時調整計劃是合適時機。 另外，政府會預留資源下年度起啟動五年計劃提升回收設施，包括逐步將「綠在區區」轉型為全天候自助回收設施，建構智慧化回收網絡，以及善用科技在廢物中提取有價值物料，轉化為環保產品的原材料。

Cytokinetics press release ( CYTK ): Q4 GAAP EPS of -$1.50 misses by $0.05 . Revenue of $17.75M (+4.8% Y/Y) beats by $9.73M . The company today announced financial guidance for 2026: GAAP Combined R&D and SG&A Expense* $830 million to $870 million Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A Expense $130 million to $120 million Click to enlarge More on Cytokinetics Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Cytokinetics: Small Label Differences With Big Commercial Stakes Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript Cytokinetics Q4 2025 Earnings Preview Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy

Key PointsOneok beat earnings expectations but gave underwhelming guidance.

Flywire Reports Fourth Quarter and Fiscal-Year 2025 Financial Results

Energy stocks were mixed late Tuesday afternoon, with the NYSE Energy Sector Index up 0.2% and the S

A group of small businesses that successfully challenged President Donald Trump ’s global tariffs before the US Supreme Court have asked lower courts to reopen the legal proceedings so that they can begin the process of seeking refunds from the government. On Tuesday, lawyers for the challengers asked the US Court of Appeals for the Federal Circuit to formalize its ruling last year declaring Trump’s so-called “reciprocal” tariffs unlawful, which a majority of the Supreme Court upheld on Feb. 20. Once that happens, the fight will return to the US Court of International Trade to determine next steps, including whether the importers must get their money back. Also on Tuesday, attorneys for the group of small businesses filed a request in the trade court asking a three-judge panel to enter a fresh injunction blocking the administration from enforcing the tariff policy and initiating the refund process. Read More: Trump Faces Tough Legal Landscape to Oppose Tariff Refunds The businesses aren’t asking the trade court for a nationwide order, saying that’s unnecessary because the government can’t impose the tariffs “on anyone without violating the Supreme Court’s decision.” But they suggested that the trade court could consider merging all of the tariff lawsuits “to ensure the fair and prompt resolution.” More than 1,500 refund lawsuits have been filed to date, according to a Bloomberg News analysis. In written filings last year, Justice Department lawyers told the trade court that the small businesses that sued would get refunds with interest if they won. “We’re trying to hold the government to their word,” Jeffrey Schwab, senior counsel and director of litigation at Liberty Justice Center, which has represented the businesses, said in an interview. Immediately after the Supreme Court announced its decision in the tariff case, Trump made comments suggesting the government might oppose paying refunds. “I guess it has to get litigated,” the president said at the time. He als...

Merck & Co. ( MRK ) shares clocked seven straight sessions of gains, as the stock was up 0.2% at $124.1 on Tuesday. The global healthcare company gained 2% in the preceding six sessions. The stock has surged over 17% so far this year and is up 15% over the past one month. Most recently, Merck announced plans to separate its core pharmaceutical division into two units as it prepares for the upcoming patent expiration of its top-selling drug. Looking at Seeking Alpha's Quant Rating, MRK has a Hold rating with a score of 3.3 out of 5. The company received A+ in the prospect of profitability, while it received F in growth. Turning to the Wall Street community , 18 analysts gave MRK a Buy and above rating. 11 analysts have given the stock a Hold recommendation, while none recommended Sell. Seeking Alpha analysts are also positive and see the stock as a Buy. More on Merck Merck: Why Investors Should Remain Bullish Despite Patent Risks Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction Merck: The Spike Doesn't Make It Overvalued CDC vaccine panel to meet in March after delay CDC Deputy Director Ralph Abraham steps down

Technology stocks led a broader market rally as artificial intelligence fears took the day off on Tuesday. The Nasdaq Composite gained 1%. Advanced Micro Devices set the tone by surging prior to the open on a deal with Meta Platforms.

格隆汇2月25日｜美股周二收盘，道指初步收涨0.76%，标普500指数涨0.77%，纳指涨1.04%。甲骨文(ORCL.N)涨3.4%，AMD(AMD.O)涨8.7%，英特尔(INTC.O)涨近6%，Paypal(PYPL.O)涨6.7%。纳斯达克中国金龙指数收涨1.37%，小鹏汽车(XPEV.N)和万国数据(GDS.O)均涨超6%。

2025 Fourth Quarter Revenue of $542.6 Million, up 12.7% year-over-year Q4 Diluted EPS (GAAP) of $0.38 , up 21.8% from $0.31 in Q4 of 2024 Q4 Adjusted Diluted EPS (Non-GAAP) (1) of $0.50 , up 15.0% from $0.44 in Q4 of 2024

Net Investment Income of $0.40 Per Share for Q4 2025;

PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on Attruby’s commercial progress.

Micron Technology to Report Fiscal Second Quarter Results on March 18, 2026 GlobeNewswire

BOISE, Idaho, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) announced today that it will hold its fiscal second quarter earnings conference call on Wednesday, Mar. 18, 2026, at 2:30 p.m. Mountain time. The call will be webcast live at http://investors.micron.com/. Webcast replays of presentations can be accessed from Micron’s Investor Relations website for approximately one year after the call. About Micron Technology, Inc. Micron Technology, Inc. is an industry leader i

Micron Technology to Report Fiscal Second Quarter Results on March 18, 2026 Yahoo Finance

Nvidia (NVDA) stock price snaps back after early dip as earnings test looms TechStock²

Will Micron Technology Stock Split? AOL.com

Why Is AMD (AMD) Stock Rocketing Higher Today TradingView

watch now VIDEO 2:49 02:49 What to expect from Trump’s State of the Union address Politics President Donald Trump is hours away from delivering his State of the Union address in the U.S. Capitol on Tuesday at 9 P.M. ET. He'll speak during a time in his presidency where his approval ratings are waning and he is eager to show results on his economic promises. This address comes at a perilous time for Trump, with polls indicating he is sinking on issues including the economy ahead of the midterm elections that loom less than nine months away. Those elections threaten to change control of Washington by Republicans. Trump will speak days after the Supreme Court overruled the tariffs that have underpinned much of his economic policy and as he awaits another decision from the high court on how much authority he has over the Federal Reserve. Trump is also weighing military action in Iran and contending with a lingering shutdown of the Homeland Security Department spurred by Democratic concerns about overreach by the department's law enforcement. Democrats are hammering Trump and the incumbent Republicans on affordability, a tactic that worked well in off-year elections in 2025 after the GOP used it to its advantage in 2024. The president's speech is expected to focus heavily on the economy, with White House Press Secretary Karoline Leavitt telling CNBC that Trump will lay out "an ambitious agenda to continue bringing the American Dream back for working people." Tuesday night will mark Trump's first official State of the Union of his second term after delivering a joint address to Congress last year, as is customary for a president's first year in office. State of the Union addresses are both a constitutional obligation and an opportunity for the president to lay out his political agenda to Congress and the public. Both chambers of Congress, Supreme Court justices, military leaders and the president's cabinet typically attend the speech, though some Democrats plan to boycott...

Tariff insecurity and AI disruption are the flavors of the week as a sharp sell-off kick-started the final week of February

Stocks Closed Higher As Meta Ties Up A Massive AMD GPU Deal Finimize

格隆汇2月25日｜美联储柯林斯：正密切关注高生产率是否有助于通胀回落。

Google has long been one of the biggest customers for Nvidia’s artificial-intelligence chips. Sundar Pichai, CEO of the internet search giant, has even specifically called out the company’s use of Nvidia’s products in 10 of his last 12 quarterly earnings calls, according to data from S&P Global Market Intelligence. There is good reason: Nvidia’s chips are in great demand and short supply.

The following companies are expected to report earnings prior to market open on 02/25/2026. Visit our Earnings Calendar for a full list of expected earnings releases.TJX Companies, Inc. (TJX)is reporting for the quarter ending January 31, 2026. The discount retail company's con

Day One reports fourth quarter and full year 2025 financial results and reaffirms 2026 outlook and revenue guidance

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability